newsfilter
← Latest News
GlobeNewswire·

SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies

  • SandboxAQ & MapLight Therapeutics (NASDAQ: MPLT) announced a strategic collaboration to discover & develop first-in-class therapies targeting a novel G protein-coupled receptor (GPCR) for central nervous system (CNS) disorders.
  • SandboxAQ received an upfront payment & is eligible for additional milestone payments totaling up to $200 million covering preclinical, development, regulatory, & commercial stages.
  • The companies will jointly conduct preclinical research, while MapLight retains exclusive rights for clinical development & commercialization of collaboration compounds.
  • SandboxAQ will utilize its AQBioSim platform to deploy large-scale AI models & high-fidelity molecular simulations for rapid receptor structure-functional activity exploration & ligand-receptor interaction prediction.
  • This approach aims to enable larger-scale compound exploration, faster Design-Make-Test-Analyze (DMTA) cycles, & accelerated convergence to potential drug candidates.
  • MapLight Therapeutics is a clinical-stage biopharmaceutical company founded to address the lack of circuit-specific pharmacotherapies for debilitating CNS disorders.
  • SandboxAQ is an independent B2B company emerging from Alphabet Inc. that delivers Large Quantitative Models (LQMs) at the intersection of AI & quantum techniques.